Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors
Por:
Moreno, V, Greil, R, Yachnin, J, Majem, M, Wermke, M, Arkenau, HT, Basque, JR, Nidamarthy, PK, Kapoor, S, Cui, XM, Giovannini, M
Publicada:
1 sep 2021
Ahead of Print:
1 sep 2021
Resumen:
Purpose: In the Phase II GEOMETRY mono-1 study, the potent and selective mesenchymal-epithelial transition (MET) inhibitor capmatinib exhibited considerable efficacy in MET exon 14 skipping (METex14)-mutated metastatic non-small cell lung cancer at a dose of 400 mg BID. The current recommended dose is 400 mg BID in tablet formulation, with or without food. This article reports the pharmacokinetic (PK) profile, safety, and tolerability of capmatinib 300 and 400 mg BID given with food in MET-dysregulated advanced solid tumors.
Methods: This multicenter, open-label, Phase I study enrolled adult patients with MET-dysregulated advanced solid tumors. In the dose escalation phase, capmatinib tablets were orally administered at a dose of 300 mg BID with food; if tolerated, the dose escalation cohort of 400 mg BID was to be opened to enrollment. In the expansion phase, patients were to be enrolled at the higher of the tolerated doses. Tablets were taken within 30 minutes of an unrestricted meal type, except on cycle 1 day 1 (C1D1) and cycle 1 day 7 (C1D7), when they were given with a high-fat meal. The primary objectives were to determine the higher of the tolerated study doses and assess PK variables, with a secondary objective of safety.
Findings: Overall, 35 patients (300 mg BID, n = 8; 400 mg BID, n = 27) with MET-dysregulated advanced solid tumors were enrolled; all patients had received prior antineoplastic therapy, and the most common primary site was lung (45.7%). Among PK-evaluable patients, the median T. for capmatinib after administration with a high-fat meal (on C1D1/C1D7) was 4.0 to 5.6 hours across doses. At steady state (C1D7), capmatinib accumulation was low across dose levels (geometric mean of accumulation ratios, 1.29-1.69), with an increase in exposure (AUC(tau) and C-max) from 300 to 400 mg BID. There were no occurrences of dose-limiting toxicity. All patients experienced at least 1 adverse event, and treatment-related adverse events occurred in 28 patients (80%; 300 mg BID, n = 6; 400 mg BID, n = 22), the most frequent of which were fatigue (37.1%) and nausea (34.3%). (C) 2021 The Authors. Published by Elsevier Inc.
Filiaciones:
Moreno, V:
Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
Greil, R:
Paracelsus Med Univ, Salzburg Canc Res Inst, Med Dept 3, Salzburg, Austria
Yachnin, J:
Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
Univ Hosp, Stockholm, Sweden
Majem, M:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
Wermke, M:
Univ Hosp Carl Gustav Carus, Med Clin 1, NCT UCC Early Clin Trial Unit, Dresden, Germany
Arkenau, HT:
Sarah Cannon Res Inst UK, Med Oncol, London, England
UCL, Inst Canc, London, England
Basque, JR:
Novartis Pharma AG, Basel, Switzerland
Nidamarthy, PK:
Novartis Healthcare Private Ltd, Hyderabad, India
Kapoor, S:
Novartis Healthcare Private Ltd, Hyderabad, India
Cui, XM:
Novartis Inst BioMed Res, E Hanover, NJ USA
Giovannini, M:
Novartis Pharmaceut, E Hanover, NJ USA
Green Published, hybrid
|